Loading...

ZYME ZYMEWORKS INC Investments/Divestments 8-K Filing

ZYMW

ZYM

ZYMEWORKS INC

(ZYME)

2023 8-K

Royalty Sale Agreement

Financial Results Update

Company Updates

Annual Meeting Results

Director Resignation & Plans

Positive Trial Results

Financial Results Announced

Clinical Discontinuation

Financial Statements

Equity Offerings

New Product Launches

Earnings Releases

Financial Results

Director Appointment

Financial Update

Annual Meeting Results

Financial Results

Management Changes

Sales Agreement with TD Sec...

Share Repurchase Program

Financial Results Announcement

Appointment of Executive Vi...

Earnings Reports

Management Change

Director Appointment

Financial Results Announcement

Director Appointment

Director Appointment and Re...

Amendment to Employment Agr...

Financial Condition Announc...

Private Placement

Annual Meeting of Stockholders

Financial Results Announcement

Termination of Agreement

Departure of Directors and ...

Termination of Agreement

Financial Results Announcement

Appointment and Resignation

Termination of Preferred St...

Departure of President and COO

Amended Jazz Collaboration ...

Financial Results Announcement

Merger of Equals

Announcement of Presentations

Appointment of Director

Termination of Material Def...

Amended and Restated Bylaws

Financial Results Announcement

External Links:

Zymeworks Inc. and Jazz Pharmaceuticals released new data from a Phase 2b trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers, showing a confirmed objective response rate of 41.3% in Cohort 1 and no responses in Cohort 2.

AI Assistant

ZYMEWORKS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.